BioNTech Launches Exchange Offer for CureVac Shares

TL;DR

BioNTech is buying CureVac shares, starting Oct 22, 2025.

AI Summary

On October 22, 2025, BioNTech SE announced the commencement of an exchange offer for all outstanding shares of CureVac N.V. This filing is a Form 6-K report submitted to the SEC.

Why It Matters

This move could signal a significant consolidation or strategic shift within the mRNA vaccine and therapeutics sector, potentially impacting competition and innovation.

Risk Assessment

Risk Level: medium — The success of the exchange offer and its impact on BioNTech's market position and financial health are subject to various factors and potential regulatory hurdles.

Key Players & Entities

• BioNTech SE (company) — Registrant and offeror
• CureVac N.V. (company) — Target of exchange offer
• October 22, 2025 (date) — Date of press release and commencement of exchange offer

FAQ

Filing Documents

• d42810d6k.htm (6-K) — 11KB
• d42810dex991.htm (EX-99.1) — 33KB
• g42810g1022202634940.jpg (GRAPHIC) — 3KB
• 0001193125-25-246740.txt ( ) — 49KB

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On October 22, 2025, BioNTech SE (the "Company") issued a press release announcing the commencement of its exchange offer for all outstanding shares of CureVac N.V. A copy of the press release is attached hereto as Exhibit 99.1. This report on Form 6-K shall be deemed to be filed and incorporated by reference in the Company's registration statement on Form F-4 (File No. 333-289468) and registration statements on Form S-8 (File Nos. 333-277105, 333-269740 and 333-253263) and to be part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Prof. Dr. Ugur Sahin By: /s/ Dr. Sierk Poetting Name: Prof. Dr. Ugur Sahin Name: Dr. Sierk Poetting Title: Chief Executive Officer Title: Chief Operating Officer Date: October 22, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

View Full Filing

View this 6-K filing on SEC EDGAR